Microcarrier Market Size, Share, Growth Report 2032

Industry Prospective:

The Microcarrier Market was worth around USD 1,682.6 million in 2021 and is estimated to grow to about USD 3,046.4 million by 2028, with a compound annual growth rate (CAGR) of approximately 10.4 percent over the forecast period. The report analyzes the Microcarrier Market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Microcarrier Market.

Request Free Sample

Microcarrier Market: Overview

Microcarriers help adherent cell development by acting as a support matrix. These microcarriers are placed in a bioreactor to aid in cell proliferation. The growing global disease burden has increased R&D activity with the goal of developing therapeutically effective drugs/vaccines, resulting in a need for microcarrier products. In addition, the growing requirement for therapeutically efficacious vaccines and pharmaceuticals is driving the worldwide microcarrier market, which has led to a growth in product demand for microcarriers. Many of the current biologics in development are aimed at indications that are dominated by small molecules and have a big patient pool. This implies that the biologics trend may infiltrate various non-traditional biologic disease areas during the projection period, benefiting from enhanced treatment efficacy.

Furthermore, this creates space for the Microcarriers market to expand. Governments throughout the world are expanding their funding in various types of healthcare research and encouraging corporations to expand their R&D activities in order to harness breakthrough technology in cell therapy.

Covid-19 Impact:

Pharmaceutical and biotech businesses, in collaboration with governments around the world, are working to solve the COVID-19 outbreak, from vaccine research to planning for pharmaceutical supply chain issues The COVID-19 pandemic aided in the adoption of microcarriers by creating a surge in demand for vaccines to combat the virus. Furthermore, routinely used medications such as hydroxychloroquine have shown a huge increase in demand for COVID-19 control. Since many wealthy countries are running low on these medications, the rising demand has created enormous potential for developers of COVID-19 management drugs. The pharmaceutical and biotechnology industries are predicted to increase significantly in the future because of the need for COVID-19 vaccines and treatment medications. COVID-19 is predicted to have a substantial impact on the Microcarrier market as a result of these considerations.

Microcarrier Market: Driver

Increasing Interest in Cell-Based Vaccines and Therapeutics

The need for cell-based vaccines is increasing, technologies are improving, and financing from private and public enterprises for cell-based research is driving the market for Microcarriers. Due to their importance in the vaccine production process, cell cultures are also expanding. Due to its shorter lead time and capacity to generate vaccinations in bigger numbers as needed, cell-based vaccines have emerged as a considerably more efficient way than others. Cell-based vaccinations have been shown in clinical trials to be as effective, efficacious, and safe as previous cell-based vaccines. Manufacturers have been attempting to boost their capability to improve their vaccines by increasing production output, which aids in cost reduction. As a result, immunizations are now available all over the world.

Request Free Sample

Microcarrier Market: Restraint

The Expensiveness of Biologics and Cell-Based Therapies

Microcarriers as well as Cell cultures are very expensive and involve a lot of R&D on any new medicines that come out. Small-scale businesses and academic institutions have limited funds and cannot always afford research. Furthermore, microcarriers always adhere to the cells, and the cells must be retrieved by a costly downstream process. These are the most significant challenges confronting the microcarrier market, and they are impeding growth. Moreover, the high expense of cell biology research and the scarcity of low-cost serum-free media are two factors that are expected to stymie industry expansion.

Microcarrier Market: Segmentation

The Microcarrier Market is segregated based on Product, Application, and End User.

By Application, the market is classified into Vaccine Manufacturing, Cell Therapy, and Others. Over the forecast period, cell therapy is expected to show the most progress. Microcarriers aid in cost-effective cell production by lowering both fixed and variable costs during large-scale manufacture. The contemporary landscape has changed as a result of technical improvements, and the importance of microcarriers in cell treatment has grown. Since the microcarriers are totally dissolved, there is no need for separation, and the downstream process proceeds smoothly. As a result, these microcarriers are regarded as advantageous beads for large-scale cell manufacturing or cell treatment applications. Another element driving the expansion of cell therapy applications of microcarriers is that companies are now focusing on the provision of microcarriers that contribute to large-scale and cost-effective production.

By End User, the market is classified into Pharmaceutical and Biotechnology Companies, Research Institutes, and CROs. The pharmaceutical and biotechnology firms category is likely to dominate the microcarrier market. This is due to the increasing usage of single-use technologies in vaccine production and the expanding application areas of microcarriers. Due to the increasing demand for research and development in life-threatening diseases, the research institutes segment is expected to be the fastest expanding category. Microcarriers are used in a variety of research institutes to aid in patient health management. Demand for microcarriers is being created by innovation, discovery, and development in the microcarriers segment, which are assisting in making patient treatment more efficient.

Report Scope:

Recent Developments

• In 2020, Thermo Fisher Scientific announced the development of a new cGMP plasmid DNA production plant in Carlsbad, California. The goal of establishing a new facility is to expand the commercial and clinical capabilities of cGMP plasmid DNA, which is commonly utilised as a raw material in the development of cell and gene therapies such as mRNA vaccinations and efficient cancer treatments.

Regional Landscape

During the projection period, North America dominated the global market. The region's leadership is due to increased R&D investments in cell and gene therapies, as well as the acceleration of vaccine development and production in the midst of the epidemic. In addition, the technological developments in company R&D led to increased utilization of microcarrier products. In addition, the United States is experiencing tremendous growth in the biologics and biosimilar industries, which is one of the primary drivers driving the microcarrier market in this area.

Additionally, Asia Pacific is expected to have a higher growth rate throughout the projection period due to an increase in chronic disease incidence, which would lead to increased investments in research such as stem cells, cell biology, and so on. The availability of research funds, technologically improved goods, and the strategic expansion of biopharmaceutical enterprises in this region are all factors driving market growth in this region.

Competitive Landscape

Some of the main competitors dominating the Microcarrier Market include - Thermo Fisher Scientific, Merck KGaA, GE Healthcare, Danaher Corporation, Corning Incorporated, Lonza, Becton, Dickinson and Company, Eppendorf AG, HiMedia Laboratories, and Sartorius AG.

Global Microcarrier Market is segmented as follows:

By Product

• Equipment
• Consumables

By Application

• Vaccine Manufacturing
• Cell Therapy
• Others

By End-User

• Pharmaceutical and Biotechnology Companies
• Research Institutes
• CROs

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa